Co-Diagnostics (CODX) shares fell about 20% to record lows after the company approved a 1-for-30 reverse stock split to regain Nasdaq's $1 minimum bid. Split-adjusted trading begins January 2, leaving about 2.1 million shares outstanding. The company has also missed revenue estimates for four straight quarters.